While it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, a new study suggests that using generative artificial intelligence could vastly accelerate the drug-development process.
Researchers have developed a unique method to screen large-scale libraries for industrially useful bacterial strains. The simple approach combines biosensors and microfluidics to quickly identify mutant strains that secrete large amounts of industrially useful proteins, opening the doors to more applications, like reasonably priced biopharmaceuticals.
